Initial unsolicited report received from the literature on 21 June 2016. This case was linked to 2016SA117942, 2016SA117944, 2016SA117945, 2016SA117946, 2016SA117947, 2016SA117948, 2016SA117949, 2016SA117950,2016SA117951, 2016SA117952, 2016SA117953, 2016SA117955, 2016SA117956, 2016SA117957, 2016SA117958, 2016SA117959, 2016SA117960, 2016SA117961,2016SA117962, 2016SA117963, 2016SA117964, 2016SA117965, 2016SA117966, 2016SA117967, 2016SA117968, 2016SA117969 (same literature). The following is verbatim from the article: Background: Anaphylaxis is a potentially life-threatening allergic reaction. The risk of anaphylaxis after vaccination has not been well described in adults or with newer vaccines in children. Objective: We sought to estimate the incidence of anaphylaxis after vaccines and describe the demographic and clinical characteristics of confirmed cases of anaphylaxis. Methods: Using health care data from the Vaccine Safety Datalink, we determined rates of anaphylaxis after vaccination in children and adults. We first identified all patients with a vaccination record from January 2009 through December 2011 and used diagnostic and procedure codes to identify potential anaphylaxis cases. Medical records of potential cases were reviewed. Confirmed cases met the Brighton Collaboration definition for anaphylaxis and had to be determined to be vaccine triggered. We calculated the incidence of anaphylaxis after all vaccines combined and for selected individual vaccines. Results: We identified 33 confirmed vaccine-triggered anaphylaxis cases that occurred after 25,173,965 vaccine doses. The rate of anaphylaxis was 1.31 (95 percent CI, 0.90-1.84) per million vaccine doses. Results: The incidence did not vary significantly by age, and there was a non-significant female predominance. Vaccine-specific rates included 1.35 (95 percent CI, 0.65-2.47) per million doses for inactivated trivalent influenza vaccine (10 cases, 7,434,628 doses given alone) and 1.83 (95 percent CI, 0.22-6.63) per million doses for inactivated monovalent influenza vaccine (2 cases, 1,090,279 doses given alone). The onset of symptoms among cases was within 30 minutes (8 cases), 30 to less than 120 minutes (8 cases), 2 to less than 4 hours (10 cases), 4 to 8 hours (2 cases), the next day (1 case), and not documented (4 cases). Conclusion: Anaphylaxis after vaccination is rare in all age groups. Despite its rarity, anaphylaxis is a potentially life-threatening medical emergency that vaccine providers need to be prepared to treat. This case involves a 55-year-old female patient who was vaccinated with dose of INFLUENZA VACCINE (manufacturer: unknown batch number, dose, route and site of administration was not reported) on an unspecified date. The patient's history of atopy was reported as none. Other medical history was not reported. Concomitant medications were not reported. On an unspecified date, six hours following vaccination, patient experienced wheeze, shortness of breath (SOB), red and itchy eyes and anaphylaxis. It was reported that patient was referred to primary care physician. Patient required emergency department or doctor visit. Lab data was not reported. Corrective treatments included oral antihistamine, oral steroid, bronchodilators and other (fluids and rest). On an unspecified date, patient recovered from events. Upon internal review the case was considered as serious because of important medical event: Anaphylaxis. Documents held by sender: none. Sender's Comments: The reported symptoms are consistent with the diagnosis of anaphylactic reaction. Time to onset is compatible with the role of the vaccine. Additional information including but not limited to the patient's previous immunization history (i.e., previous immunizations and any adverse events following immunizations), medical history, concomitant medication, vaccine details, and allergy testing to identify the culprit allergen are needed to further assess this case. Based on the information available, a role of the vaccine cannot be ruled out.